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Letters to the Editor
OThe TM6SF2 rs58542926 T allele is signiﬁcantly associated with
non-alcoholic fatty liver disease in ChineseTo the Editor:
A recent study has identiﬁed that a missense variant in TM6SF2
gene (rs58542926: C>T, NP_001001524.2:p. E167K) is signiﬁ-
cantly associated with non-alcoholic fatty liver disease (NAFLD)
[1]. Further analyses suggested that this variant is also signiﬁ-
cantly associated with NAFLD disease progression [2,3].
However, most of the studies thus far were performed in non-
Asian populations, leaving out the question as to whether this
variant also confers a risk of NAFLD in Asians (particularly East
Asians), the largest population in the world. A most recent study
led by Wong and colleagues examined the impact of TM6SF2 vari-
ant on NAFLD in a Chinese cohort, where the TM6SF2 167K allele
was concluded to have a limited effect on NAFLD [4]. This was
deemed to be attributed to the low minor allele frequency
(MAF = 7% in their study) as well as the confounding effect of
the PNPLA3 I148M variant, another signiﬁcant risk factor for
NAFLD that are replicated among all major human populations
[5]. In order to further verify the effect of this newly discovered
allele in NAFLD, we conducted a case-control study in a commu-
nity-based Han Chinese population.
The rs58542926 polymorphism was genotyped in blood DNA
samples from NAFLD patients (n = 384) and healthy controls
(n = 384) that were collected in the health examination center
of Shanghai Jiao Tong University Afﬁliated First People’s
Hospital (Shanghai, China). Genotyping was conducted using a
Taqman-based assay (Life Technologies, CA, USA). Both the case
and control groups consisted of 229 males and 155 females, with
a mean age of 45 ± 13 years. The NAFLD diagnosis was made
based on ultrasonographic examinations according to the guide-
line deﬁned by the Chinese National Consensus Workshop on
NAFLD [6]. The examination was performed by one experienced
operator who was blinded to both clinical and biochemical eval-
uations of the patients. No histological data based on liver biopsy
were available for these patients. For each individual, detailed
data for ultrasonographic examination of the upper abdominal
organs, clinical data for a comprehensive physical examination
as well as a questionnaire for demographic, disease history, fam-
ily history, smoking and alcohol intake information were all col-
lected. The NAFLD patients were selected by excluding the cases
with other known causes of steatosis, including heavy alcohol
intake (>20 g/day), the use of medications known to contribute
to hepatic steatosis, and hepatitis B and C virus infection.
Patients with a high likelihood to have other known liver diseases
were also excluded. Randomly selected healthy volunteers from
the same population with normal liver enzymes, liver ultrasound
and without any major illnesses were chosen as controls. The
cases and controls were 1:1 matched according to their gender
and age information. All enrolled individuals are self-reported
Han Chinese and reside in the Shanghai metropolitan area.
Informed consent was obtained from all participants. The study
was approved by the ethical committees of the Shanghai Jiao
Tong University and strictly conforms to the principles of the
Declaration of Helsinki.
Consistent with Wong’s results, the TM6SF2 167K allele has a
similarly low frequency in our dataset (MAF = 6.6%). However, we
still observed a signiﬁcant association between TM6SF2 167K
allele and NAFLD (p = 0.0007) after adjustment for age, sex, body
mass index and status of diabetes (Table 1). Furthermore, to clar-
ify the independent effect of the TM6SF2 allele on NAFLD, we con-
trolled the PNPLA3 rs738409 polymorphism, which was
signiﬁcantly associated with NAFLD in our data (p = 0.0002, data
not shown). Our analysis showed that rs58542926 remained to
be associated with NAFLD (p = 0.0004) after conditioning on
rs738409 (Table 1). Moreover, several genome-wide association
studies have shown that a variant in NCAN (rs2228603), whose
locus is near TM6SF2, is strongly associated with NAFLD [7,8].
However, rs2228603 is not signiﬁcantly associated with NAFLD
in our samples (p = 0.1, data not shown). After conditioning on
this variant, the TM6SF2 rs58542926 variant still remains signiﬁ-
cant (p = 0.001) in our data (Table 1).
In summary, we demonstrated that in a Han Chinese pop-
ulation cohort, the TM6SF2 167K allele has a similar allele fre-
quency as reported in Caucasian populations (7%) [1–3] but
higher than that in African-Americans (3.4%) [1], Hispanic-
Americans (4.7%) [1], and Argentinians (5.5%) [9]. Our data sug-
gests that this variant signiﬁcantly contributes to increased
NAFLD risk in Chinese population, independent of the PNPLA3
rs738409 and NCAN rs2228603 polymorphisms. This observation
further highlights the independent and potentially causal role of
rs58542926 in the disease biology of NAFLD. However, further
investigation is needed in East Asian populations to test whether
it is also involved in NAFLD disease progression and severity,
especially using biopsy-characterized samples.
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Table 1. Association between TM6SF2 rs58542926 variant and NAFLD.
Genotype count Statistical analysis*
Genotype CC CT TT Unconditioned Condition on rs738409 Condition on rs2228603
Control 333 33 0 OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Case 302 65 0 2.2 (1.4-3.4) 0.0007 2.3 (1.4-3.6) 0.0004 2.1 (1.4-3.4) 0.001
⁄Associations were tested using logistic regression with adjustment for age, sex, BMI and status of diabetes.
OR, odds ratio; CI, conﬁdence interval.
Is it worthy of switching to PegIFN alfa-2a in patients achieving
virological suppression with entecavir?
To the Editor:
We read with great interest the article ‘‘Switching from entecavir
to PegIFN alfa-2a in patients with HBeAg positive chronic hepati-
tis B: A randomized open-label trial (OSST trial)’’ [1]. This elegant
study assessed the rates of HBeAg seroconversion and HBsAg loss
in patients with well-controlled HBV DNA replication and serum
HBeAg <100 PEIU/ml on long-term entecavir (ETV) therapy after
switching to a ﬁnite course of PegIFN alfa-2a. Qin Ning et al. [1]
demonstrated that switching to a ﬁnite course of PegIFN alfa-2a
signiﬁcantly increased rates of HBeAg seroconversion and
HBsAg loss and concluded this is a potential alternative to indeﬁ-
nite nucleos(t)ide analogue (NA) therapy.
Many chronic hepatitis B patients are treated with ETV in
China. Some of them hope to stop this inﬁnite treatment if a ﬁnite
course of treatment can give similar or better outcomes with a
reasonable cost and minimal adverse effects. In Shenzhen,
patients receiving sequential therapy with NA and PegIFN are
not rare. However, there are several concerns about this article
and its approach. First, the absolute difference in HBeAg serocon-
version rate was only 8.8%. In other words, the number to treat for
one HBeAg seroconversion is 11. All these patients have to suffer
the adverse effects of PegIFN. It is well known that hepatic decom-
pensation and even death has been reported during IFN treat-
ment. We should also pay special attention to the adverse effect
of stopping of ETV. Hepatic decompensation or liver failure was
not recorded in the study given the sample size. Recently, one of
my patients developed acute on chronic liver failure during
PegIFN treatment after stopping ETV and adefovir (ADV) which
was reported on in a local hepatology meeting. The effect of an
overlapping period of ETV and PegIFN on safety and efﬁcacy
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